Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | TPO | P07202 | 1/20 | 0.36 |
| ▸ | EPX | P11678 | 1/20 | 0.36 |
| ▸ | LPO | P22079 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15779486 | 0.80 | LMNA (0.53) | MAP4K4CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL15771133 | 0.77 | ATR (0.49) | — | |
| SCHEMBL20176873 | 0.75 | TGFBR1 (0.46) | MAP4K4TGFBR1CYP11B1CYP11B2 | |
| SCHEMBL641410 | 0.75 | MAPT (0.46) | KDM4EALDH1A1GAA | |
| SCHEMBL641107 | 0.75 | MAPT (0.56) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL23010322 | 0.74 | ALDH1A1 (0.41) | AURKATTKAURKBINCENPCA12 | |
| SCHEMBL26018939 | 0.74 | MAP4K4 (0.45) | MAP4K4TGFBR1P2RX3MPOTPO | |
| SCHEMBL30309931 | 0.74 | CYP1A2 (0.49) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL9853825 | 0.74 | CYP1A2 (0.49) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL29972517 | 0.74 | LMNA (0.60) | CYP11B1CYP11B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| EP-1960347-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | Sterix Limited (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007003934-A2 | 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS | STERIX LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003934-A2 | 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS | STERIX LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | MAP4K4 4541/4885TGFBR1 1442/4885P2RX3 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.